Raise closed, search for fresh raises on Seedstage

Shaker Heights, OH

Advancing a digital diagnostic platform that rapidly detects multiple diseases from a single saliva sample using biosensor technology.

• Digital diagnostics platform: Uses patented graphene biosensors instead of traditional chemical testing.
• Multiplex disease detection: Designed to identify multiple pathogens simultaneously from a single sample.
• Portable and user-friendly: Bluetooth-enabled device suitable for home and clinical use.
• Scalable business model: Razor-razorblade approach with reusable hardware and single-use cartridges.
• Global health impact: Aims to expand testing access in underserved markets like Africa.

IdentifySensors Biologics is raising capital to advance the commercialization of its Check4 diagnostic platform, which is designed to digitally detect and differentiate multiple diseases from a single saliva sample using proprietary biosensor technology. The company’s patented sensors eliminate the need for traditional chemical testing, offering instead a printed graphene-based sensor that works without reagents and enzymatic amplification. The portable Bluetooth-enabled device is intended to deliver hospital-grade diagnostic accuracy at home or point-of-care settings. The funds raised will support clinical trials, regulatory submissions, manufacturing, and initial market entry, with an emphasis on expanding access to affordable, high-accuracy diagnostics.

With a goal of disrupting the $16 billion molecular testing market, IdentifySensors Biologics is targeting a wide range of infectious diseases including respiratory, gastrointestinal, and sexually transmitted infections. The company is employing a razor-razorblade model, with a reusable device paired with single-use diagnostic cartridges. This scalable approach allows the technology to be adapted for various diseases while maintaining a consistent manufacturing process. Pending FDA approval, the company plans to first launch in clinical settings and later expand into consumer markets. The Check4 platform’s digital architecture positions it as a faster, lower-cost, and more accessible alternative to PCR tests, with potential for significant impact in underserved regions and broader global healthcare markets.

Company Info

IdentifySensors Biologics develops portable digital diagnostic devices that detect multiple infections from saliva using solid-state biosensors.

IdentifySensors Biologics is developing a digital diagnostic platform, Check4, that uses graphene-based electronic biosensors to detect and differentiate multiple pathogens from a single saliva sample. The sensors eliminate the need for chemical reagents and can provide highly accurate results in minutes, aiming to match or exceed the performance of PCR tests. The core technology is embedded in a portable Bluetooth device designed for both point-of-care and at-home use, offering a scalable solution for rapid molecular diagnostics.

The business model follows a razor-razorblade approach, with a reusable reader device and disposable test cartridges targeting various infectious diseases. The platform is adaptable for multiple applications, ranging from respiratory illnesses to sexually transmitted infections, and is intended to bring affordable, reliable testing to global markets, including initial deployments in Africa. IdentifySensors aims to replace slow, expensive chemical testing with faster, digital-based diagnostics.